Related Experiment Videos
[Immunisation against influenza with a new subunit vaccine tested on children at risk (author's transl)]
Insights
Sandovac, a new subunit vaccine, demonstrated excellent tolerance and efficacy in children and juveniles. Antibody responses against influenza A and B strains were significant, indicating effective immune stimulation.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Influenza remains a significant public health concern, necessitating effective vaccination strategies.
- Subunit vaccines offer a promising approach for influenza prevention due to their safety profile.
Purpose of the Study:
- To evaluate the efficacy and tolerance of Sandovac, a novel subunit influenza vaccine, in pediatric populations.
- To assess the immunogenicity of Sandovac by measuring antibody responses to key influenza antigens.
Main Methods:
- A clinical trial involving 104 children and juveniles aged 2.25 to 17 years.
- Administration of two Sandovac dosages (1000 and 2000) with rigorous monitoring for side effects.
- Measurement of antibody titers against hemagglutinin and neuraminidase before and after vaccination.
Main Results:
- Sandovac was well-tolerated, with no significant local or systemic side effects reported.
- High conversion rates for hemagglutination-inhibiting antibodies were observed: 100% for influenza A (Victoria) and 86% for influenza B (Hong Kong).
- Significant increases in geometric mean antibody titers were noted for both hemagglutinin and neuraminidase antigens against both influenza A and B strains.
Conclusions:
- Sandovac is a safe and immunogenic subunit vaccine for pediatric use.
- The vaccine effectively elicits protective antibody responses against relevant influenza strains.
- Sandovac represents a valuable new option for pediatric influenza immunization.
Abstract:
The efficacy and tolerance of Sandovac, a new subunit vaccine, was tested in 104 children and juveniles aged 2 1/4 to 17 years, at five children's clinics. Sandovac 1000 was given to 39 children, Sandovac 2000 to 65. The vaccine was well tolerated, no appreciable side effects--local or systemic--having been recorded. The efficacy of Sandovac was checked by determining the antibody titre against haemagglutinin and neuraminidase in 36 children before and 28 days after vaccination with SAndovac 1000. The conversion rate with haemagglutination-inhibiting antibody titres type A strain Victoria was 100% and type B strain Hong Kong 86%. The geometric mean values rose by a factor of 29 for type A and 7.4 for type B. For the neuraminidase-inhibiting antibodies the factors were 3.15 with type A and 5.83 with type B. Titre increases by a factor of at least 1.5 occurred in 75 and 84%, respectively of vaccinated children.